Jefferies downgraded Vigil Neuroscience (VIGL) to Hold from Buy with a price target of $8, down from $19, after Sanofi (SNY) agreed to acquire the company for $8 per share in cash plus a non-tradeable contingent value right entitling the holder to potentially receive an additional $2.00 per share in cash.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VIGL:
- Vigil Neuroscience downgraded to Neutral from Outperform at Wedbush
- Vigil Neuroscience Enters Merger Agreement with Sanofi
- Vigil Neuroscience downgraded to Neutral from Buy at Guggenheim
- Vigil Neuroscience downgraded to Market Perform from Outperform at William Blair
- Vigil Neuroscience downgraded to Market Perform from Outperform at Citizens JMP